Compare Quest Diagnostics Inc (DGX) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs VICI Properties Inc — how do they compare? Quest Diagnostics Inc trades at $237.15 (market cap $26.21B), while VICI Properties Inc trades at $25.95 (market cap $28.61B). The key difference: Quest Diagnostics Inc and VICI Properties Inc are close in size by market cap, and VICI Properties Inc pays the higher dividend (6.93%). Which is the better fit depends on your goals.
| DGX | VICI | |
|---|---|---|
Market Cap | $26.21B | $28.61B |
Sector | Health | Real Estate |
52-Week High | $238.50 | $33.78 |
52-Week Low | $173.49 | $25.94 |
Enterprise Value | $31.97B | $46.16B |
Dividend Yield | 1.45% | 6.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
VICI Properties trades at $25.99, down 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings with an EPS miss but revenue beat, while maintaining strong profitability margins near 67%. Recent news highlights a $1.75 billion notes offering and positive dividend coverage, with analysts largely bullish.
Outlook remains positive given a 6.6% dividend yield, low P/E of 10.07, and consensus price target of $29.83 implying 15% upside. Risks include earnings volatility, high leverage with $843.61M interest expense, and macroeconomic sensitivity affecting real estate valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
